MNV-BM-PLC
/ Minovia Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
June 27, 2025
A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
(clinicaltrials.gov)
- P1 | N=0 | Withdrawn | Sponsor: Minovia Therapeutics Ltd. | Trial completion date: Jan 2024 ➔ Dec 2024 | Not yet recruiting ➔ Withdrawn | Trial primary completion date: Mar 2022 ➔ Dec 2024
Trial completion date • Trial primary completion date • Trial withdrawal • Metabolic Disorders
August 31, 2021
A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion
(clinicaltrials.gov)
- P1; N=6; Not yet recruiting; Sponsor: Minovia Therapeutics Ltd.; Initiation date: Jan 2021 ➔ Mar 2022
Clinical • Trial initiation date • Metabolic Disorders
1 to 2
Of
2
Go to page
1